SciClone to Acquire NovaMed Pharma for up to $105 Million

SciClone Pharmaceuticals of California has acquired Shanghai-based NovaMed Pharmaceuticals, a privately held company, for a price that could reach as much as $105 million. Both companies are engaged in the registration and distribution of western pharmaceuticals in China. Before the transaction, SciClone issued guidance for 2011 revenues of $100-$103 million. Now, the company expects pro forma revenues to reach $140-$145 million. More details.... Stock Symbol: (NSDQ: SCLN)     Share this with colleagues:   var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});